Who Owns Neurogene Stock?
NASDAQ: NGNEHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 97.59%
- Institutions (% of float)
- 104.91%
- Held by insiders
- 6.98%
- Institutional holders
- 164
- Institutions 93.0%
- Insiders 7.0%
- Public and other 0.0%
Who owns Neurogene stock?
Institutional investors own about 97.6% of Neurogene's shares, spread across 164 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.98% of NGNE.
The largest institutional holders are Samsara BioCapital, LLC (8.58%), Casdin Capital, LLC (7.72%) and Redmile Group, LLC (7.06%). Together, the top 10 institutions control 57.8% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their NGNE positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of NGNE
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Samsara BioCapital, LLC | 1.72M | 8.58% | 0.0% |
| Casdin Capital, LLC | 1.55M | 7.72% | +8.8% |
| Redmile Group, LLC | 1.41M | 7.06% | -3.3% |
| RTW Investments LP | 1.36M | 6.81% | 0.0% |
| EcoR1 Capital, LLC | 1.27M | 6.35% | 0.0% |
| Blackrock Inc. | 1.06M | 5.29% | +5.3% |
| Baker Bros. Advisors, LP | 991.69K | 4.96% | 0.0% |
| Balyasny Asset Management LP | 818.71K | 4.09% | +14.0% |
| Trails Edge Capital Partners, LP | 714.88K | 3.57% | -8.7% |
| Toronto Dominion Bank | 681.34K | 3.40% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of NGNE
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 397.79K | 1.99% |
| iShares Trust-iShares Russell 2000 ETF | 291.84K | 1.46% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 218.78K | 1.09% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 177.20K | 0.89% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 126.73K | 0.63% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 124.03K | 0.62% |
| iShares Trust-iShares Biotechnology ETF | 118.94K | 0.59% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 104.41K | 0.52% |
| iShares Trust-iShares Russell 2000 Value ETF | 104.05K | 0.52% |
| Meridian Fund Inc-Meridian Small Cap Growth Fund | 75.86K | 0.38% |
Frequently asked questions
Who is the largest shareholder of Neurogene?
Samsara BioCapital, LLC is the largest institutional shareholder of NGNE, owning 8.58% of shares outstanding (1.72M shares) as of its latest 13F filing.
What percentage of Neurogene is owned by institutions?
Institutions own about 97.6% of NGNE shares and 104.9% of the public float.
How much of Neurogene do insiders own?
Insiders, such as officers and directors, own about 6.98% of NGNE shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.